WO2015087083A1 - Intranasal pharmaceutical compositions of polymeric nanoparticles - Google Patents

Intranasal pharmaceutical compositions of polymeric nanoparticles Download PDF

Info

Publication number
WO2015087083A1
WO2015087083A1 PCT/GB2014/053684 GB2014053684W WO2015087083A1 WO 2015087083 A1 WO2015087083 A1 WO 2015087083A1 GB 2014053684 W GB2014053684 W GB 2014053684W WO 2015087083 A1 WO2015087083 A1 WO 2015087083A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
intranasal pharmaceutical
composition according
pharmaceutically acceptable
intranasal
Prior art date
Application number
PCT/GB2014/053684
Other languages
English (en)
French (fr)
Inventor
Darshana S. JAIN
Amrita N. BAJAJ
Original Assignee
Cipla Limited
Turner, Craig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Limited, Turner, Craig filed Critical Cipla Limited
Publication of WO2015087083A1 publication Critical patent/WO2015087083A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Definitions

  • the present invention relates to intranasal pharmaceutical compositions comprising polymeric nanoparticles of anticancer drugs, a process for preparing such intranasal pharmaceutical compositions and their use in the treatment of tumours, especially brain tumours.
  • Malignant brain tumours are comprised of a number of malignancies including gliomas, medulloblastomas, primary central nervous system lymphomas and brain metastases. Most brain tumours are gliomas which originate in the glial cells. Gliomas can be described as low grade which have slow growth, intermediate grade which are more aggressive and high grade which are the most aggressive.
  • Astrocytoma is the most common type of glioma which usually originates from astrocytes that are located in the cerebrum and cerebellum. Glioblastoma multiforme is a form of very aggressive astrocytoma.
  • Glioblastomamultiforme are the most common form of primary brain tumours occurring at an incidence rate of 14 cases per 1 ,00,000 adults in United States of America. Glioblastomamultiforme is the most dangerous type of brain tumour that remains poorly prognosed despite the progress in chemotherapy and radiation.
  • Glioblastomamultiforme is carried out by administering oral alkylating agents and nitrosoureas, especially by administration of temozolomide and bevacizumab.
  • BBB Blood Brain Barrier
  • tumours extremely difficult.
  • the approaches for the better treatment of brain tumours include pharmacological approach and physiological approach.
  • Physiological based approach involves disruption of BBB using osmotic agents and convection enhanced delivery (CED)
  • pharmacological approach includes modification of chemical structure of the drug by synthesizing a prodrug.
  • the pharmaceutical approach can be employed which focusses on bypassing the BBB by using a novel, practical, simple and non-invasive approach namely intranasal delivery.
  • the neural connections between the nasal mucosa and the brain provide a unique pathway for the non-invasive delivery of therapeutic agents to the CNS. This pathway also allows drugs which do not cross the BBB to enter the CNS and it eliminates the need for systemic delivery and thereby reducing unwanted systemic side effects.
  • one of the characteristics that distinguish anticancer agents from other drugs is the frequency and severity of side effects at therapeutic doses. These side effects may be acute or chronic, self-limited, permanent, mild or potentially life threatening. Hence management of these side effects is of utmost importance because they affect the treatment, tolerability and overall quality of life.
  • Common toxicities that may be encountered are haematological, gastrointestinal, skin and hair follicle toxicity, nervous system toxicity, local toxicity, metabolic abnormalities, hepatic toxicity, urinary tract toxicity, cardiac toxicity, pulmonary toxicity, gonadal toxicity etc.
  • Measures that can ameliorate the toxicities of anticancer drugs include dose reduction, use of alternate drugs or their analogues, growth factors, and cytoprotective agents. However, employing any of these measures might affect the treatment and ultimately the therapeutic efficacy of the desired anticancer agent s.
  • anticancer drugs cannot greatly differentiate between cancerous and normal cells, leading to systemic toxicity and adverse effects.
  • rapid elimination and widespread distribution into non targeted organs and tissues require the administration of the anticancer drug in large doses, which may not be economical as well as may exhibit nonspecific toxicity to such non targeted organs.
  • Nanoparticles of anticancer agents exhibit several advantages in the delivery of such agents by virtue of their small average particle size. Such nanoparticles are hydrophobic in nature and can cross the BBB to some extent.
  • PLA-MAA nanoparticles of methotrexate prepared by double emulsion solvent evaporation technique as disclosed in this article are unstable and not homogenous which may ultimately affect the delivery of the anticancer drug to the site of action.
  • nanoparticles comprising anti-cancer agents in prior art is only discussed in the context of aiding the passage of the anti-cancer agents across the blood brain barrier with the nanoparticles.
  • the difficulties while formulating nasal compositions include an enzymatically active and low pH nasal epithelium, mucosal irritation and patient to patient variability caused by nasal pathology.
  • anticancer drugs such as methotrexate, 5-FU and raltitrexed which have been delivered using intranasal delivery failed to discriminate between tumour tissues and normal tissues thus leading to the toxicity of normal neural tissues. Further, the concentrations of such anticancer drug solutions in the brain are low due to minimised residence time of such intranasal formulations.
  • the inventors of the present invention have acknowledged the aforementioned drawbacks associated with known intranasal compositions comprising anti-cancer drugs, and have sought ways of addressing them.
  • the inventors have appreciated that it would be useful to provide an intranasal pharmaceutical composition of anticancer drugs that exhibits immediate or prolonged release, has an increased residence time in the nasal mucosa, is mucoadhesive, and specifically targets the brain tumour cells over healthy cells.
  • An object of the present invention is to provide intranasal pharmaceutical compositions comprising polymeric nanoparticles of anticancer drugs.
  • Another object of the present invention is to provide intranasal pharmaceutical compositions comprising polymeric nanoparticles of anticancer drugs which are mucoadhesive.
  • Another object of the present invention is to provide intranasal pharmaceutical compositions comprising polymeric nanoparticles of anticancer drugs having improved surface area and solubility.
  • Another object of the present invention is to provide intranasal pharmaceutical compositions comprising polymeric nanoparticles of anticancer drugs requiring a reduced dose of anti-cancer drug in the pharmaceutical composition.
  • Another object of the present invention is to provide intranasal pharmaceutical compositions comprising polymeric nanoparticles of anticancer drugs having reduced side effects.
  • Another object of the present invention is to provide intranasal pharmaceutical compositions comprising polymeric nanoparticles of anticancer drugs that effectively bypass the Blood Brain Barrier.
  • Another object of the present invention is to provide the use in the treatment of brain tumours by administering intranasal pharmaceutical compositions comprising polymeric nanoparticles of anticancer drugs exhibiting increased residence time in the nasal cavity and improved targeting of brain tumour cells.
  • an intranasal pharmaceutical composition comprising one or more polymeric nanoparticles of one or more anti-cancer drugs and optionally one or more pharmaceutically acceptable excipients.
  • the one or more anti-cancer drugs comprise methotrexate.
  • the one or more polymeric nanoparticles comprises polylactic acid (PLA), polylacticglycolic acid (PLGA), or any combination thereof.
  • a process for the preparation of intranasal pharmaceutical composition of the invention comprises formulating one or more polymeric nanoparticles comprising one or more anti-cancer agents with one or more pharmaceutically acceptable excipients to provide the intranasal pharmaceutical composition.
  • the process comprises encapsulating one or more anti-cancer agents within a polymer to provide one or more polymeric nanoparticles comprising the one or more anti-cancer agents. More preferably, the process comprises solvent evaporation.
  • an intranasal pharmaceutical composition of the invention for use in the treatment of brain tumours.
  • the brain tumours comprise glioblastomamultiforme (GBM) or anaplastic astrocytomas (AA).
  • the use of intranasal pharmaceutical compositions of the invention in the manufacture of a medicament for treating brain tumours Preferably, the brain tumours comprise glioblastomamultiforme (GBM) or anaplastic astrocytomas (AA).
  • the method comprises administering intranasal pharmaceutical compositions of the invention to a patient in need thereof.
  • the brain tumours comprise glioblastomamultiforme (GBM) or anaplastic astrocytomas (AA).
  • Figure 1 In vitro release of methotrexate (MTX) and nasal methotrexate nanoparticles (MTX- NP).
  • MTX methotrexate
  • MTX- NP nasal methotrexate nanoparticles
  • the pure MTX demonstrated a 100% release from the dialysis bag in just less than two hours as compared to the, MTX-NP which continued to release MTX for more than 72 hours. 50% of the trapped MTX was released in ⁇ 16 hours followed by the release of the remaining trapped MTX.
  • FIG. 1 Pharmacokinetic study of methotrexate (MTX) and nasal methotrexate nanoparticles (MTX-NP).
  • MTX methotrexate
  • MTX-NP nasal methotrexate nanoparticles
  • the drug concentration of the intranasally administered MTX- NP achieved in the brain is four times higher as compared to intransally administered pure MTX at 24 hours thus demonstrating the ability of nanoparticles to deliver the drug to the brain.
  • results obtained for lung tissue deposition indicates that intranasally administered pure drug gets distributed in the lungs following the trachea- bronchial deposition.
  • the amount of drug deposited in the lung was significantly lowered when the drug was administered in the form of mucoadhesive nanoparticles due to increased residence of the nanoparticles in nasal cavity.
  • FIG 4 Cytotoxicity assay of methotrexate (MTX), nasal methotrexate nanoparticles (MTX_NP) and plain nanoparticles (P-NP)
  • Intranasal delivery provides a practical, non-invasive method for delivering anticancer drugs to the brain because of the unique anatomic connections provided by the olfactory and trigeminal nerves.
  • Intranasally administered anticancer drugs can reach the brain parenchyma, spinal cord, and cerebrospinal fluid (CSF) within minutes by using an extracellular route through perineural and/or perivascular channels along the olfactory and trigeminal nerves without binding to any receptor.
  • CSF cerebrospinal fluid
  • the intranasal delivery not only bypasses the BBB, but also provides rapid delivery of the anticancer drugs to the CNS, avoids hepatic first-pass drug metabolism, reduces unwanted systemic side effects and eliminates the need for systemic delivery of such anticancer drugs.
  • intranasal delivery is very convenient as patients can self-administer such compositions enhancing patient compliance, the only limitation being that the nasal cavity is cleared at regular intervals (approximately after every 20 minutes) by the mucociliary clearance mechanism which may lead to the loss of anticancer drug
  • polymeric nanoparticles protect the anticancer drugs from degradation in nasal enzymatic milieu and provide better absorption through the nasal membrane. Nanoparticles by virtue of their small size demonstrate numerous advantages. Further, the loss of anticancer drugs from the nanoparticles by mucociliary movement of the nasal cavity can be prevented by fabricating the mucoadhesive particles.
  • the fabricated nanoparticles comprising the anticancer drugs are preferably formulated in a thermosensitive base that gels upon administration into the nasal cavity, adheres to the nasal mucosa, thus increasing residence time of the drug in the nasal cavity.
  • thermosensitive base preferably dropped or sprayed as fine droplets into the nasal cavity and spread over a larger surface area on the nasal mucosa in solution state.
  • the solution After being administered into nasal cavity, the solution transforms into a viscous hydrogel at body temperature, which ultimately decreases the nasal mucociliary clearance rate by adhering to the nasal mucosal membrane increasing the residence time of the drug in the nasal mucosa.
  • This behaviour is due to the presence of the thermosensitive base, which is not used in previously known intranasal compositions comprising anticancer drugs.
  • the formation of the viscous hydrogel also provides immediate or prolonged release of the drug.
  • intranasal pharmaceutical compositions are stable, exhibits reduced side effects as well as decreases the number of applications to the nasal cavity ultimately leading to improved patient compliance.
  • Biodegradable polymeric nanoparticulate drug delivery systems have the ability to target therapeutic drugs to the site of action as well as reduce the toxicity or side effects and are preferred due to their non-toxic as well as non-immunogenic nature, enabling them to act as potential carriers.
  • nanoparticulate based polymeric drug delivery system are advantageous due to adjustable properties such as biodegradability, good biocompatibility and amphiphilic characteristics, controlled release, targeted delivery and therapeutic impact.
  • polymeric biodegradable materials used in such nanoparticulate drug delivery system are natural or synthetic in origin and are degraded in vivo, either enzymatically or non-enzymatically or both, to produce biocompatible, toxicologically safe by-products which are further eliminated by the normal metabolic pathways.
  • the basic category of biomaterials used in drug delivery can be broadly classified as synthetic biodegradable polymers, semi-synthetic and natural, such as, but not limited to, the -hydroxy acids such aspolylactic acid and polylacticcoglycolic acid;, polyanhydrides; naturally occurring polymers such as complex sugars such as hyaluronan and chitosan; inorganics such as hydroxyapatit); polycaprylactones, polymalic acids, polybutylcyanoacrylates, sugars, dextrans, human serum albumin, bovine serum albumin, cellulose derivatives such as hydroxypropylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, methylcellulose polymers hydroxyethylcellulose, sodium carboxymethylcellulose, carboxymethylene and carboxymethylhydroxyethylcellulose; acrylics like acrylic acid, acrylamide, and maleic anhydride polymers, acacia, gum tragacanth, locust bean gum, guar gum, or karaya gum,
  • the polymers may be present in an amount ranging from about 0.1 % to about 35% by weight of the composition.
  • Polylactic acid (PLA) and polylacticcoglycolicacid (PLGA) have been widely used to synthesize polymeric nanoparticles due to their biodegradability, non-immunogenic, non-toxic and biocompatibility properties.
  • PLA it is a polymer designed form lactic acid monomer which has its own mechanism of degradation within the body.
  • the hydrophobic nature of the polymer is further suitable for transit of the nanoparticles through the fencing system of the brain.
  • PLGA is most widely used because of its long clinical experience, favourable degradation characteristics and possibilities for sustained drug delivery. Further, degradation of PLGA can be employed for obtaining sustained release of drugs at desirable doses by implantation without surgical procedures. Additionally, it is possible to alter the physical properties of the polymer- drug matrix by controlling the relevant parameters such as polymer molecular weight, ratio of lactide to glycolide and drug concentration to achieve a desired dosage and release interval depending upon the drug type.
  • PLA and PLGA are the polymers that are employed in forming polymeric nanoparticles for use in the intranasal pharmaceutical compositions of the invention.
  • the intranasal pharmaceutical compositions, according to the present invention comprises PLA and PLGA nanoparticles of anticancer drugs.
  • compositions comprising polymeric nanoparticles of anticancer drugs are preferably engineered to have an affinity for target tissues through passive or active targeting mechanisms.
  • the intranasal pharmaceutical compositions comprising polymeric nanoparticles of anticancer drugs preferably exhibits reduced side effects compared with known pharmaceutical compositions comprising anti-cancer drugs.
  • the intranasal pharmaceutical compositions comprising polymeric nanoparticles of anticancer drugs preferably demonstrate lesser side effects due to higher amount of drug deposition in the brain owing to high residence time and low mucociliary clearance as compared to the amount of drug deposition in the lung.
  • the intranasal pharmaceutical compositions comprising polymeric nanoparticles of anticancer drugs can exhibit immediate or prolonged release.
  • compositions comprising polymeric nanoparticles of anticancer drugs of the invention are preferably mucoadhesive.
  • Mucoadhesiveness increases the residence time of the intranasal pharmaceutical compositions by lowering the mucociliary clearance and also by inhibiting the ciliary movement.
  • the intranasal pharmaceutical compositions comprising polymeric nanoparticles of anticancer drugs of the invention also exhibits enhanced BBB passage.
  • the intranasal pharmaceutical compositions comprising polymeric nanoparticles of anticancer drugs of the invention may preferably have a reduced dose compared with known pharmaceutical compositions in the art comprising anti-cancer drugs.
  • Anticancer drugs that may be used in the pharmaceutical compositions of the invention may comprise but are not limited to, alkylating agents, anti-metabolites, anti-microtubule agents, topoisomerase inhibitors or antitumor antibiotics, DNA linking agents, biological agents and bisphosphonates, or any combination thereof.
  • Suitable alkylating agents comprise, one or more of, but not limited to, nitrogen mustards, nitrosoureas, tetrazines, aziridines, and non-classical alkylating agents.
  • Nitrogen mustards include mechlorethamine, cyclophosphamide, melphalan, chlorambucil, ifosfamide, busulfan.
  • Nitrosoureas include N-Nitroso-N-methylurea, carmustine, lomustine, semustine, fotemustine, streptozotocin, dacarbazine.bendamustine, procarbazine, mitozolomide, temozolomide, thiotepa, mytomycin, diaziquone and the like or combinations thereof.
  • Suitable anti-metabolites comprise, one or more of, but not limited to, methotrexate, pemetrexed, raltitrexed, asparaginase, fluorouracil, capecitabine, cytarabine, gemcitabine, decitabine, vidaza, fludarabine, nelarabine, cladribine, clofarabine, pentostatin, thioguanine, mercaptopurine and the like or combinations thereof.
  • Suitable anti-microtubule agents comprise, one or more, but not limited to vincristine, vinblastine, paclitaxel, docetaxel, etoposide, irinotecan, topotecan, vinorelbine and the like or combinations thereof.
  • Suitable topoisomerase inhibitors or antitumor antibiotics comprise, one or more, but are not limited to actinomycin D, bleomycin, plicamycin, mitomycin, doxorubicin, daunorubicin, epirubicin, idarubicin, pirarubicin, aclarubicin, mitoxantrone, actinomycin, bleomycin and the like or combinations thereof.
  • Suitable DNA linking agents comprise, one or more, but are not limited to, cisplatin, oxaliplatin, carboplatin and the like or combinations thereof.
  • Suitable biological agents comprise, one or more, but are not limited to, alemtuzamab, BCG, bevacizumab, cetuximab, denosumab, erlotinib, gefitinib, imatinib, interferon, ipilimumab, lapatinib, panitumumab, rituximab, sunitinib, sorafenib, emsirolimus, trastuzumab and the like or combinations thereof.
  • Suitable bisphosphonates that may be used comprise, one or more, but are not limited to, clodronate, ibandronic acid, pamidronate, zolendronic acid and the like or combinations thereof.
  • Suitable other anticancer drugs that may be used comprise, one or more, but are not limited to, anastrozole, abiraterone, amifostine, bexarotene, bicalutamide, buserelin, cyproterone, degarelix, exemestane, flutamide, folinic acid, fulvestrant, goserelin, lanreotide, lenalidomide, letrozole, leuprorelin, medroxyprogesterone, megestrol, mesna, octreotide, stilboestrol, tamoxifen, thalidomide, tiptorelin and the like or combinations thereof.
  • the one or more anti-cancer drugs comprise an anti-metabolite.
  • the antimetabolite comprises methotrexate.
  • the intranasal pharmaceutical composition comprises either PLA or PLGA nanoparticles of methotrexate.
  • Combinations of PLA and PLGA may also be used to form the polymeric nanoparticle comprising the methotrexate.
  • metalhotrexate is used in broad sense to include not only “methotrexate” per se but also its pharmaceutically acceptable derivatives thereof. Suitable derivatives include pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable isomers, pharmaceutically acceptable esters, pharmaceutically acceptable anhydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable polymorphs, pharmaceutically acceptable prodrugs, pharmaceutically acceptable tautomers and/or pharmaceutically acceptable complexes thereof.
  • the methotrexate may be present in an amount ranging from about 0.1 % to about 20% by weight of the composition.
  • methotrexate is indicated in the treatment of neoplastic diseases, psoriasis and Rheumatoid Arthritis including Polyarticular-Course Juvenile Rheumatoid Arthritis.
  • methotrexate is employed for treating neoplastic diseases such as gestational choriocarcinoma, chorioadenomadestruens and hydatidiform mole.
  • neoplastic diseases such as gestational choriocarcinoma, chorioadenomadestruens and hydatidiform mole.
  • methotrexate is indicated in the prophylaxis of meningeal leukemia.
  • intranasal pharmaceutical compositions comprising PLA as well as PLGA nanoparticles of methotrexate especially for the treatment of Glioblastomamultiforme (GBM) and anaplastic astrocytomas (AA), wherein the intranasal pharmaceutical composition exhibits targeted delivery of methotrexate to the tumour cells and thereby eliminating the delivery of methotrexate to non-targeted organs.
  • GBM Glioblastomamultiforme
  • AA anaplastic astrocytomas
  • nasal pharmaceutical composition is used to refer to nasal dosage forms, such as but not limited to, powders, powder for reconstitution, snuffs, sprays, solutions, suspensions, ointments, drops, in-situ gel, aerosols, ointments, microspheres, creams, gels, patches, films and the like.
  • Suitable solvents for reconstitution include, but are not limited to, water, purified water for injection, sterile saline solution, dextrose solution, Ringers solution and the like.
  • the inventors of the present invention have further observed that the PLA as well as PLGA nanoparticles in the intranasal pharmaceutical compositions exhibit enhanced penetration of methotrexate to the site of action, i.e. it exhibits enhanced penetration of methotrexate to the brain via the nasal route by increasing the residence time of the drug in methotrexate in the nasal cavity.
  • the polymeric nanoparticles for use in the invention have an average particle size of less than or equal to 2000 nm. More preferably, the polymeric nanoparticles for use in the invention have an average particle size of less than or equal to 2000 nm, less than or equal to 500 nm and most preferably less than or equal to about 250 nm, or 200 nm.
  • average particle size refers to the average diameter of the particles.
  • the present invention thus provides intranasal pharmaceutical compositions comprising PLA as well as PLGA nanoparticles of methotrexate wherein such nanoparticles have an average particle size of less than or equal to about 2000 nm, preferably less than or equal to about 1000 nm, more preferably less than or equal to about 500 nm and most preferably less than or equal to about 250 nm.
  • average particle size refers to the average diameter of the particles.
  • all particles have a particle size of less than or equal to about 500 nm, preferably less than or equal to about 200 nm.
  • particles refers to an individual particle of the polymeric nanoparticle comprising methotrexate or the polymeric nanoparticles comprising particles of methotrexate or the polymeric nanoparticles comprising methotrexate compositions and/or mixtures thereof.
  • the particles of the present invention can be obtained by any of processes such as but not limited to milling, precipitation, homogenization, high pressure homogenization, spray-freeze drying, supercritical fluid technology, double emulsion-solvent evaporation, emulsion-solvent evaporation, emulsion-solvent diffusion, PRINT (Particle replication in non-wetting templates), thermal condensation, ultrasonication, interfacial polymerisation, , spray drying and combinations thereof.
  • the particles of the present invention are prepared by the process of emulsion solvent evaporation with high pressure homogenization.
  • the polymeric nanoparticles for use in the intranasal pharmaceutical compositions of the invention are prepared by, the process of solvent evaporation.
  • This process can comprise dissolving methotrexate or other anti-cancer drugs and PLA PLGA or other suitable polymers in suitable solvents followed by emulsification.
  • the emulsion may then be subjected to high pressure homogenization and is further evaporated to produce methotrexate encapsulated PLA/PLGA nanoparticles or nanoparticles of other anti-cancer drugs encapsulated in PLA/PLGA or other suitable polymers.
  • methotrexate encapsulated PLA/PLGA nanoparticles are optionally freeze dried.
  • the process of solvent evaporation can comprise dissolving the one or more anticancer drugs such as methotrexate and one or more suitable polymers such as PLA/PLGA in suitable solvents followed by emulsification and evaporation to produce nanodispersions of the one or more anti-cancer drugs such as methotrexate which are further incubated with surface modifiers to form surface modified drug encapsulated PLA/PLGA nanoparticles.
  • the anticancer drug encapsulated PLA/PLGA nanoparticles obtained by the aforementioned processes may be formulated to obtain the desired nasal dosage form.
  • the anticancer drug encapsulated PLA/PLGA nanoparticles obtained by the aforementioned processes are co-precipitated in an aqueous stabiliser medium serving as gelling agent to obtain "one- pot” nanoparticulate dispersion. Further the obtained nanoparticles can be blended with gelling agents to obtain the nasal gel.
  • Suitable excipients may be used for formulating the nasal dosage forms according to the present invention.
  • Surfactants may be used in intranasal compositions of the invention which act as stabilizers to increase the stability of the composition. These are capable of stabilizing the particle thus inhibiting its aggregation and agglomerate formation. Further, they also enhance the BBB passage of the PLA/PLGA nanoparticles. Suitable amphoteric, non-ionic, cationic or anionic surfactants may be included in the pharmaceutical composition of the present invention.
  • Surfactants that can be used in the compositions of the invention may comprise one or more of, but not limited to non-ionic triblock copolymers or poloxamers (Synperonics ® , Lutrols ® , Pluronics ® and Kolliphor ® ), Polysorbates, Sodium tauroglycolate, Sodium dodecyl sulfate (sodium lauryl sulfate), Lauryl dimethyl amine oxide, Docusate sodium, Cetyltrimethylammoniumbromide (CTAB), Polyethoxylated alcohols, Polyoxyethylenesorbitan, Octoxynol, N, N-dimethyldodecylamine-N-oxide, Hexadecyltrimethylammonium bromide, Polyoxyl 10 lauryl ether, Brij, Bile salts (sodium deoxycholate, sodium cholate), Polyoxyl castor oil, Nonylphenolethoxylate Cyclodextrins, Lecithin,
  • Carboxylates Sulphonates, Petroleum sulphonates, alkylbenzenesulphonates, Naphthalenesulphonates, Olefin sulphonates, Alkyl sulphates, Sulphates, Sulphated natural oils and fats, Sulphated esters, Sulphated alkanolamides, Alkylphenols, ethoxylated and sulphated, Ethoxylated aliphatic alcohol, polyoxyethylenesurfactants, carboxylic esters Polyethylene glycol esters, Anhydrosorbitol ester and it's ethoxylated derivatives, Glycol esters of fatty acids, Carboxylic amides, Monoalkanolamine condensates, Polyoxyethylene fatty acid amides, Quaternary ammonium salts, Amines with amide linkages, Polyoxyethylene alkyl and alicyclic amines, ⁇ , ⁇ , ⁇ , ⁇ tetrakis substituted ethylenediamines 2- alkyl 1-
  • the surfactants may be present in an amount ranging from about 0.01 % to about 20% by weight of the composition.
  • Solubilisers may also be used in the compositions of the invention. Solubilisers may be used to enhance the solubility of the anticancer agent and then encapsulate the solubilized anticancer agent in PLA/PLGA nanoparticles. Suitable solubilisers that may be used in intranasal compositions of the invention, include, but are not limited to polyethylene glycol, propylene glycol and their derivatives, Solutol HS, Caryol PGAMC, Transcutol P, Lauroglycol PGMC, hydrogenated fatty acid esters, coconut fatty acid diethanolamide, medium and/or long chain fatty acids or glycerides, monoglycerides, diglycerides, triglycerides, structured triglycerides, soyabean oil, peanut oil, corn oil, corn oil mono glycerides, corn oil di glycerides, corn oil triglycerides, polyethylene glycol, caprylocaproylmacroglycerides, caproyl
  • the solubilisers may be present in an amount ranging from about 0.01 % to about 20% by weight of the composition.
  • Surface modifiers may also be used in the compositions of the invention. Surface modifiers enhance the BBB passage of the PLA/PLGA nanoparticles.
  • Such surface modifiers that may be used in intranasal compositions of the invention include, but are not limited to, polyethylene glycols and its derivatives (N-hydroxysuccinimide activated PEG, succinimidyl ester of PEG propionic acid, succinimidyl ester of PEG butanoic acid, and succinimidyl ester of PEG alpha- methylbutanoate and the like or mixtures thereof), propylene glyclos, poloxamers, polysorbates, Cetyltrimethylammoniumbromide (CTAB) or mixtures thereof.
  • CTAB Cetyltrimethylammoniumbromide
  • Ligands may also be used in compositions of the invention. Ligands enhance the BBB passage of the PLA PLGA nanoparticles as well as target the tumour cells. Such ligands that may be used in compositions of the invention, include, but are not limited to, folic acid, sugars, amines, antibodies, insulin, transferrin, diphtheria toxin or mixtures thereof in its own form or in conjugated form.
  • Suitable solvents/co-solvents or vehicles that may be employed, in the pharmaceutical composition include, but are not limited to, dichloromethane, acetonitrile, ethyl acetate, acetone, propylene carbonate, water, glycerine, coconut fatty acid diethanolamide, medium and/or long chain fatty acids or glycerides, monoglycerides, diglycerides, triglycerides, structured triglycerides, soyabean oil, peanut oil, corn oil, corn oil mono glycerides, corn oil di glycerides, corn oil triglycerides, polyethylene glycol, caprylocaproylmacroglycerides, caproyl 90, propylene glycol, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene castor oil derivatives, castor oil, cottonseed oil, olive oil, safflower oil, peppermint oil, coconut oil, palm seed oil, beeswax, oleic acid,
  • Cryoprotectants for use in the compositions of the invention may comprise one or more of sucrose, lactose, sorbitol, dextrose, trehalose, mannose, glycine, ammonium acetate, poloxamers and the like or combinations thereof.
  • one or more cryoprotectants may be present in an amount ranging from about 0.5% to about 20% by weight of the total composition.
  • thermosensitive bases as discussed above may be used in the compositions of the invention.
  • thermosensitive bases comprise one or more of poloxamers, carbopol, poly(/V- isopropyl acrylamide) (PNIPAA), poly(/VJv-diethylacrylamide) (PDEAA) poly(/V-vinlycaprolactam) (PVCL), poly[2-(dimethylamino)ethyl methacrylate] (PDMAEMA)and polyethylene glycol (PEG), also called polyethylene oxide (PEO), PEG methacrylate polymers (PEGMA), poly methacrylic acid and its derivatives, and the like or combinations thereof.
  • poloxamers carbopol, poly(/V- isopropyl acrylamide) (PNIPAA), poly(/VJv-diethylacrylamide) (PDEAA) poly(/V-vinlycaprolactam) (PVCL), poly[2-(dimethylamino)ethyl methacrylate] (PDMAEMA
  • Gelling agents may also be used in compositions of the invention. Suitable gelling agents, that may be employed, in the intranasal pharmaceutical compositions include, but are not limited to, carbomer, xanthan gum, sodium alginate (Manugel DMB), Carbopol ® , polycarbophil, polysaccharides, natural gums, acacia, tragacanth, starch, cellulose derivatives such as carboxy methyl cellulose, hydroxyl propyl methyl cellulose, hydroxyl propyl ethyl cellulose (Methocel), methacrylate polymers, polyvinyl pyrrolidone, polyvinyl alcohol, bentonite, alginic acid, ethyl cellulose, gelatin, guar gum, hydroxyl ethyl cellulose, hydroxyl propyl cellulose, methylcellulose, hydroxyethyl methylcellulose, glycerylbehenate, sodium carboxymethylcellulose, algae extracts, gums, polysacc
  • the present invention also provides a method of treating brain tumours by administering intranasal pharmaceutical compositions comprising polymeric nanoparticles of methotrexate.
  • the present invention also provides the use in the treatment of brain tumours by administering intranasal pharmaceutical composition comprising polymeric nanoparticles of methotrexate.
  • Methotrexate and the polymer were solubilized in dichloromethane.
  • step (1) The solution obtained in step (1) was emulsified with Poloxamer 188.
  • step (3) The emulsion obtained in step (2) was subjected to high pressure homogenization.
  • step (3) The organic solvent in the emulsion obtained in step (3) was evaporated and the residue was filled in the appropriate container and lyophilized and further processed into the desired nasal drug delivery formulations.
  • Methotrexate and the polymer were solubilized in dichloromethane.
  • step (1) The solution obtained in step (1) was emulsified with Carbopol 934.
  • step (3) The emulsion obtained in step (2) was subjected to high pressure homogenization.
  • step (3) The organic solvent in the emulsion obtained in step (3) was evaporated and the residue was filled in the appropriate container suitable and lyophilized and further processed into the desired nasal drug delivery formulations
  • Methotrexate PLA nanoparticles obtained either through the process as exemplified in example (A) and (B) may be sniffed into the nasal cavity or reconstituted with a suitable solvent to be administered in the form of nasal spray or nasal drops.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/GB2014/053684 2013-12-13 2014-12-12 Intranasal pharmaceutical compositions of polymeric nanoparticles WO2015087083A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3918/MUM/2013 2013-12-13
IN3918MU2013 IN2013MU03918A (enrdf_load_stackoverflow) 2013-12-13 2014-12-12

Publications (1)

Publication Number Publication Date
WO2015087083A1 true WO2015087083A1 (en) 2015-06-18

Family

ID=52282753

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2014/053684 WO2015087083A1 (en) 2013-12-13 2014-12-12 Intranasal pharmaceutical compositions of polymeric nanoparticles

Country Status (2)

Country Link
IN (1) IN2013MU03918A (enrdf_load_stackoverflow)
WO (1) WO2015087083A1 (enrdf_load_stackoverflow)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109364029A (zh) * 2018-12-04 2019-02-22 临沂大学 一种白藜芦醇微球及其制备方法
CN110327302A (zh) * 2019-07-23 2019-10-15 大连工业大学 一种增强越橘花色苷稳定性的壳聚糖-果胶复合体系的制备方法及其应用
CN111388406A (zh) * 2020-03-24 2020-07-10 西安力邦医药科技有限责任公司 氟维司群或其衍生物可注射递药贮库及其制备方法和应用
CN112004534A (zh) * 2018-02-05 2020-11-27 罗马大学 在脑肿瘤治疗中使用的化合物
CN112390876A (zh) * 2020-11-30 2021-02-23 广西冠峰生物制品有限公司 一种降低人血白蛋白货架期铝离子释放的方法
WO2021062204A1 (en) * 2019-09-27 2021-04-01 Greenmark Biomedical Inc. Bisphosphonate loaded starch nanoparticle
CN113512236A (zh) * 2021-05-24 2021-10-19 广州市尚信净化工程有限公司 一种氧化刺槐豆胶-卡拉胶微球及其制备方法
CN115040689A (zh) * 2022-05-11 2022-09-13 上海摩漾生物科技有限公司 一种高流动性羟基磷灰石纳米材料及其制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1815851A1 (en) * 2006-02-03 2007-08-08 NanoDel Technologies GmbH Nanoparticles designed for drug delivery
WO2009048958A2 (en) * 2007-10-08 2009-04-16 The Board Of Regents Of The University Of Texas System Methods and compositions involving chitosan nanoparticles
WO2009108932A2 (en) * 2008-02-28 2009-09-03 The Johns Hopkins University Selectin ligands useful in the diagnosis and treatment of cancer
WO2010014117A1 (en) * 2008-07-30 2010-02-04 Nitto Denko Corporation Drug carriers
WO2010059963A2 (en) * 2008-11-21 2010-05-27 The Board Of Regents Of The University Of Texas System Preparation and methodology of silk fibroin nanoparticles
WO2011041897A1 (en) * 2009-10-06 2011-04-14 Angiochem Inc. Compositions and methods for the transport of therapeutic agents
US20130337067A1 (en) * 2012-06-15 2013-12-19 The Royal Institution For The Advancement Of Learning/Mcgill University Non-viral nanoparticle-based delivery system

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1815851A1 (en) * 2006-02-03 2007-08-08 NanoDel Technologies GmbH Nanoparticles designed for drug delivery
WO2009048958A2 (en) * 2007-10-08 2009-04-16 The Board Of Regents Of The University Of Texas System Methods and compositions involving chitosan nanoparticles
WO2009108932A2 (en) * 2008-02-28 2009-09-03 The Johns Hopkins University Selectin ligands useful in the diagnosis and treatment of cancer
WO2010014117A1 (en) * 2008-07-30 2010-02-04 Nitto Denko Corporation Drug carriers
WO2010059963A2 (en) * 2008-11-21 2010-05-27 The Board Of Regents Of The University Of Texas System Preparation and methodology of silk fibroin nanoparticles
WO2011041897A1 (en) * 2009-10-06 2011-04-14 Angiochem Inc. Compositions and methods for the transport of therapeutic agents
US20130337067A1 (en) * 2012-06-15 2013-12-19 The Royal Institution For The Advancement Of Learning/Mcgill University Non-viral nanoparticle-based delivery system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TALEGAONKAR S. ET AL.: "Intranasal delivery: an approach to bypass the blood brain barrier", INDIAN JOURNAL OF PHARMACOL., vol. 36, no. 3, June 2004 (2004-06-01), pages 140 - 147, XP002736662 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112004534A (zh) * 2018-02-05 2020-11-27 罗马大学 在脑肿瘤治疗中使用的化合物
CN109364029A (zh) * 2018-12-04 2019-02-22 临沂大学 一种白藜芦醇微球及其制备方法
CN110327302A (zh) * 2019-07-23 2019-10-15 大连工业大学 一种增强越橘花色苷稳定性的壳聚糖-果胶复合体系的制备方法及其应用
WO2021062204A1 (en) * 2019-09-27 2021-04-01 Greenmark Biomedical Inc. Bisphosphonate loaded starch nanoparticle
US20220370372A1 (en) * 2019-09-27 2022-11-24 Greenmark Biomedical Inc. Bisphosphonate loaded starch nanoparticle
CN111388406A (zh) * 2020-03-24 2020-07-10 西安力邦医药科技有限责任公司 氟维司群或其衍生物可注射递药贮库及其制备方法和应用
CN111388406B (zh) * 2020-03-24 2024-02-23 西安力邦医药科技有限责任公司 氟维司群或其衍生物可注射递药贮库及其制备方法和应用
CN112390876A (zh) * 2020-11-30 2021-02-23 广西冠峰生物制品有限公司 一种降低人血白蛋白货架期铝离子释放的方法
CN113512236A (zh) * 2021-05-24 2021-10-19 广州市尚信净化工程有限公司 一种氧化刺槐豆胶-卡拉胶微球及其制备方法
CN115040689A (zh) * 2022-05-11 2022-09-13 上海摩漾生物科技有限公司 一种高流动性羟基磷灰石纳米材料及其制备方法

Also Published As

Publication number Publication date
IN2013MU03918A (enrdf_load_stackoverflow) 2015-09-25

Similar Documents

Publication Publication Date Title
WO2015087083A1 (en) Intranasal pharmaceutical compositions of polymeric nanoparticles
Varghese et al. Cubosomes in cancer drug delivery: A review
AU2017239541B2 (en) Use of polymeric excipients for lyophilization or freezing of particles
Deepak et al. Nanofiber in transmucosal drug delivery
RU2523714C2 (ru) Полимерные системы доставки действующих веществ
Zhang et al. Doxorubicin-loaded star-shaped copolymer PLGA-vitamin E TPGS nanoparticles for lung cancer therapy
Torres-Martínez et al. Drugs loaded into electrospun polymeric nanofibers for delivery
Tuomela et al. Production, applications and in vivo fate of drug nanocrystals
CN102421451A (zh) 苯达莫司汀环多糖组合物
Noor et al. Formulation and evaluation of ondansetron HCl nanoparticles for transdermal delivery
JP2008513363A (ja) ナノ粒子を含む送達媒体
EP2895147B1 (en) Rapidly dissolving pharmaceutical composition
JP2025013635A (ja) 粘膜表面における活性薬剤の増強された輸送のための低張性ヒドロゲル製剤
US20130202712A1 (en) Compositions And Methods For Treating Or Preventing Immuno-Inflammatory Disease
KR20080095130A (ko) ｐＨ 민감성 블록공중합체를 이용한 약물전달체 제조 및응용
WO2016020697A1 (en) Pharmaceutical compositions of polymeric nanoparticles
JP6426195B2 (ja) 治療用化合物の結晶形態及びその使用
ES2358493A1 (es) Nanopartículas pegiladas que comprenden una molécula biológicamente activa y sus aplicaciones.
Patel et al. Advances in novel parentral drug delivery systems
Zhu et al. Intranasal administration of pullulan-based nanoparticles for enhanced delivery of adriamycin into the brain: In vitro and in vivo evaluation
Chen et al. Nanocrystals for Intravenous Drug Delivery: Composition Development, Preparation Methods and Applications in Oncology
US10864280B2 (en) Nanodroplet compositions for the efficient delivery of anti-cancer agents
Kumari et al. Formulation Considerations and Application of Nanostructured Lipid Carriers (NLC) for Ocular Delivery.
Benedini et al. Nanodevices for facing new challenges of medical treatments: stimuli-responsive drug delivery systems
Serpe et al. Innovative formulations for the controlled and site-specific delivery of antiinflammatory drugs

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14824068

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14824068

Country of ref document: EP

Kind code of ref document: A1